Aoxing Pharmaceutical Company Inc.
AXN
AXN was delisted on the 16th of October, 2017.
7 hedge funds and large institutions have $77K invested in Aoxing Pharmaceutical Company Inc. in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
30% less funds holding
Funds holding: 10 → 7 (-3)
40% less capital invested
Capital invested by funds: $128K → $77K (-$51K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$9.99K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$20K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$6K |
| 4 |
Bank of New York Mellon
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $36K | +$9.99K | +27,600 | +32% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $18K | -$16K | -44,114 | -43% |
|
3
Barclays
London,
United Kingdom
| $8K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $7K | +$8.3K | +22,945 | New |
|
|
EWM
5
Evercore Wealth Management
New York
| $4K | – | – | – |
|
6
Creative Planning
Overland Park,
Kansas
| $2K | – | – | – |
|
|
FWM
7
Focused Wealth Management
Newburgh,
New York
| $2K | – | – | – |
|
|
PAM
8
Panagora Asset Management
Boston,
Massachusetts
| – | -$20K | -49,068 | Closed |
|
|
VKH
9
Virtu KCG Holdings
New York
| – | -$6K | -16,012 | Closed |
|
|
10
Bank of New York Mellon
New York
| – | -$5K | -11,664 | Closed |
|
AXN Hedge Fund Activity: Q2 2017 in Review
7 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical Company Inc. (AXN) for Q2 2017, worth a combined $77K — down 40% from $128K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AXN and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $9.99K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $20K sold.
- 7 institutional investors held Aoxing Pharmaceutical Company Inc. (AXN) as of Q2 2017, down from 10 in Q1 2017.
- Funds reported $77K of Aoxing Pharmaceutical Company Inc. stock for Q2 2017, down 40% quarter-over-quarter.
- 1 fund opened new Aoxing Pharmaceutical Company Inc. positions in Q2 2017 and 4 closed out, a net change of -3 holders.
- The largest Aoxing Pharmaceutical Company Inc. buyer in Q2 2017 was Renaissance Technologies, an estimated $9.99K added.
- The largest Aoxing Pharmaceutical Company Inc. seller in Q2 2017 was Panagora Asset Management, an estimated $20K sold.
Based on aggregated 13F filings for Q2 2017.